Chronic kidney disease is associated with increased all‐cause mortality in transvenous lead extraction: A systematic review and meta‐analysis. Issue 1 (14th December 2022)

• Record Type: Journal Article
• Authors: Tan, Min Choon; Talaei, Fahimeh; Trongtorsak, Angkawipa; Lee, Justin Z.; Rattanawong, Pattara
• Is Part Of: Pacing and clinical electrophysiology. Volume 46:Issue 1(2023)
• Page Start: 66
• Page End: 72
• Publication Date: 2022-12-14
• Subjects: chronic kidney disease -- end‐stage renal disease -- lead extraction -- mortality -- outcome assessment; Cardiac pacing -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1111/pace.14631
• Languages: English
• ISSNs: 0147-8389

Abstract

Abstract: Background: The impact of chronic kidney disease (CKD) or end‐stage renal disease (ESRD) on patients receiving transvenous lead extraction (TLE) is not well‐established. We performed a systematic review and meta‐analysis to explore the association between CKD and all‐cause mortality in TLE. Methods: We searched the databases of PubMed and EMBASE from inception to April 2022. Included studies were published TLE studies that compared the risk of mortality in CKD patients compared to control patients. Data from each study were combined using the random‐effects model. Results: Eight studies (5, 013 patients) were included. Compared with controls, CKD patients had a significantly higher risk of overall all‐cause mortality (hazard ratio [HR] = 2.14, 95% confidence interval [CI]: 1.65–2.77, I 2 = 51.1%, p < .001). The risk of overall all‐cause mortality increased with the severity of CKD for nonspecific CKD (HR = 2.01, 95% CI: 1.49–2.69, I 2 = 53.4, p < .001) and ESRD (HR = 2.79, 95% CI: 1.85–4.23, I 2 = 0%, p < .001). The risk of all‐cause mortality in CKD is double at follow‐up ≤1 year (HR = 1.99, 95% CI: 1.29–3.09, I 2 = 50.9%, p = .002) and higher at follow‐up >1 year (HR = 2.36, 95% CI: 1.63–3.42, I 2 = 59.7%, p < .001). Conclusions: Our meta‐analysis demonstrates a significantly increased risk of overall all‐cause mortality in patients with CKD who underwent TLE compared to controls.